ABIVAX SA Price & Performance (ABVX)

Abivax has announced a cash position of €144.2 million as of December 31, 2024, ensuring operations until Q4 2025. The funds will support its Phase 3 ABTECT trial for ulcerative colitis, with enrollment completion expected in Q2 2025 and key results anticipated in Q3 2025. R&D spending surged to €146.5 million.12

Wall Street analysts project a potential 360.5% upside for Abivax SA stock, driven by promising earnings revisions and confidence in its pipeline. The stock recently rose 29.5% to $7.60, with price targets ranging from $12 to $50. Analysts also highlight the company's advancements in treating inflammatory bowel diseases.32

Abivax reported a net loss of €176.2 million for FY2024, widening from €147.8 million in 2023. The loss is attributed to higher R&D expenses and operational costs as the company advances its Phase 3 trials. Operating income, however, rose to €12.5 million, reflecting research credits and subsidies.45